**Audrey's Life Science Meeting Picks for April 23, 2017 – June 2017**
**Complimentary Service of AudreysNetwork.com**
**April 23, 2017**
**********

**PBSS Symposium, Monday, April 24, 2017**
*Topic: "Mechanistic Drug Metabolism for Drug Candidate Optimization – A Mini-symposium for Medicinal Chemists and DMPK* Scientists"
Organizers: Cyrus Khojasteh and Donglu Zhang (Genentech)
Date and Time: April 24, 2017, 8:45-17:00
Location: Crowne Plaza, Foster City, CA
Registration fee (USD): Minisymposium fee: $195;
Registration: http://www.PBSS.org
Registration deadline:4/20/2017 (it will close sooner if the seating cap is reached)

Topic Description
Drug metabolism and pharmacokinetics (DMPK) plays an integral role in drug discovery. At drug discovery stage, mechanistic drug metabolism studies contribute to generating drug candidates with optimal ADME properties and in some cases it allows for overcome potential drug development obstacles such as toxicity and DDI that are often encountered in drug discovery and development. In this one-day symposium, multiple examples will be presented to illustrate the utilities of mechanistic drug metabolism in moving discovery and development programs forward. Medicinal chemists and drug metabolism scientists should greatly be benefited from participating in this symposium.

Tentative topics and speakers:
Morning: 8:45-12:00
Overview on drug metabolism and its role in lead optimization - Cyrus Khojasteh, Genentech
Hepatocyte spheroid models and applications in drug metabolism - Jinping Gan, BMS
Sponsor presentation
Drug metabolism tools to assess bioactivation potential of drug candidates - minimizing metabolism-related DILI or genotoxicity - Zhoupeng Zhang, Merck
Prediction of circulating drug metabolites - Ming Hu, University of Houston

Afternoon: 1:15-5:00
Inhibition of endogenous metabolic pathways leading to toxicities - Donglu Zhang, Genentech
Sponsor presentation
Discovery of Bioavailable Pim Inhibitors by Mitigating Intestinal Metabolism – Gina Wang, Genentech
Metabolism-based structure-activity relationship analysis for identification of a PI3K inhibitor clinical candidate devoid off target hepatotoxicity - Raju Subramanian, Gilead
Minimizing reversible and time-dependent CYP inhibition of NAMPT (nicotinamide phosphoribosyltransferase) inhibitors - Mark Zak, Genentech
Carboxylic acid bioactivation via glucuronides/acyl CoA's and application in drug discovery – Mark Grillo, Amgen

**Bio2Device Group, Tuesday Morning, April 25, 2017**

Topic: "A Clinical Trial Roadmap: Who, What, When, and How – Practices, Perspectives and Personal Insights"

Speaker: David Larwood, CEO,Valley Fever Solutions
Date and Time: Tuesday, April 25, 2017, 8:30 am
Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale
There are no fees nor registration required for morning meetings.

Event Details:
While many of us conceptually understand the clinical trial process, a deeper dive will provide essential information regarding the parties involved, the risks, structuring and optimizing clinical archicture, design, efficiency, visibility, and more. What are the recommended practices? What is Just-inTime Monitoring? How should you manage your supply chain? How do you select the best CRO? The key is to understand the elements and thus ensure smooth navigation throughout the complex clinical trial landscape and journey. There are a myriad of drugs in clinical trials, each with a story to tell.
Valley Fever Solutions' (VFS) first-in-class compound, Nikkomycin Z (NikZ) is being developed as a dramatically superior potential cure for Valley Fever (VF), a painful and debilitating orphan disease. Collectively, the market for anitfungals across a spectrum of similar disease organisms approaches $1B. Broadly and worldwide, the market reaches $6B. With Orphan Product designation, NikZ's Phase I trial results have been very promising, and VFS has a "fast track" plan to proof of concept in 10 months.They anticipate showing human efficacty working with an existing trial at the NIH. VFS expects to be a good candidate for an additional $1.5M FDA orphan drug product trial grant in 2017. Join us and learn from a true expert's professional and personal journey.

Speaker Bio
David Larwood has been a chemist for decades, most recently leading Valley Fever Solutions since 2007 as its CEO. His PhD research at UC San Francisco included the world's first PEGylated liposomes, later leading to Doxil. He was the first to make suitable PEGylated lipids. Earlier, at UC San Diego, he was the first ever to make Iotrolan, a contrast agent still in commercial use 37 years later.
Valley Fever Solutions is a small startup working first on a new and improved treatment for Valley Fever (coccidioidomycosis). Since securing grant support to continue with Phase II trials, Mr. Larwood has been leading improving the API manufacturing process, working on drug product, planning for clinical trials, and organizing the trials.
Mr. Larwood moved away from being a bench scientist when he took a law degree. He advised well known companies on patent matters until he moved to a position at Apple Computer for four years. He took an executive role at a startup, again in an IP role. He then moved to another startup taking Verisity Design public as General Counsel, continuing in that role through a successful acquisition in 2005. David also received an MBA in entrepreneurship from UC Berkeley and Columbia University.
Mr. Larwood is the third of his family to be involved in Valley Fever. His father is a clinician who developed an interest in the disease decades ago when the family moved to Bakersfield, California, a hot spot for Valley Fever. His mother started a foundation in about 1998 and raised some $20M for research into vaccines for Valley Fever. Her chief scientist was the program manager at Shaman running the Nikkomycin Z drug development project. Timing was perfect for Mr. Larwood to join Valley Fever Solutions in 2007 to drive that project forward.

**********

**BioScience Forum, Wednesday Evening, April 26, 2017**

Topic: "The Right Medicine for the Right Patient -
Challenges and Opportunities of Precision Medicine"

Speaker: Dietmar Berger, M.D., Ph.D., Senior Vice President, Global Head of Clinical Development for Hematology/Oncology Product Development
Roche/Genentech
Date and Time: Wednesday, April 26, 2017, 6:00-9:00 pm
6 pm - 7 pm networking
7 pm - 8 pm dinner
8 pm - 9 pm presentation
Location: The Holiday Inn, 275 S Airport Blvd, South San Francisco, California 94080, USA
Event Registration ($3 service fee will apply)
Pre-Registration
$50.00
On-Site Registration
$60.00
Pre-Registration ends Monday, April 24th, at 9 pm
Cash or check accepted on the day of the event
$10 discount for full-time students

Or you can pay with a check made out to "BioScience Forum" and sent to:
BioScience Forum
1442A Walnut Street, #308
Berkeley, CA 94709-1405
Please do not mail checks later than Thursday, April 20th
If paying with check, do not complete online registration with Cvent
WIB, Thursday Evening, April 27, 2017
Register at

Topic Description
Oncology has changed dramatically over recent years – a deeper understanding of tumor drivers, cancer biology and immunology has led to a plethora of new treatment approaches, including targeted molecules and cancer immunotherapies. State of the art diagnostics predict efficacy of treatments across cancer types and independent of "standard" tumor classifications by tissue of origin. In the future, the confluence of cutting-edge medicines, comprehensive diagnostics and genomic sequencing, and the application of new technologies and data sources (including real-world data) will lead to an even more personalized paradigm. These developments pose both opportunities and challenges from a pharmaceutical and biotechnology perspective.

Dr. Dietmar Berger will speak about Genentech's approach to this changing oncology landscape, including development of novel targeted therapies, integration of diagnostic platforms, and personalized cancer immunotherapy. Novel trial designs and rapid application of new biomarker insights have led to accelerated pathways for clinical testing and regulatory submissions. Dr. Berger will discuss the mechanism of action of selected immunotherapy and small molecule products in the clinic and the progress of selected clinical candidates in solid tumors and hematology.

Speaker Bio
Dietmar Berger is Senior Vice President and Global Head, Product Development, Clinical Hematology and Oncology at Roche/Genentech. In this role, Dr. Berger leads the medical strategy for the company's global clinical development portfolio for cancer medicines. Dr. Berger was formerly Vice President of Global Clinical

Development for Roche/Genentech's HER2 breast cancer franchise and was instrumental in the development and marketing approvals of two breast cancer medicines across three new indications.

Dr. Berger has more than 20 years of experience in oncology research and development, including as Head of the Clinical Research Center at the University Medical Hospital, Freiburg, Germany. He has held leadership positions at several global pharmaceutical companies and also received the Cancer Award of the German Cancer Society for his research on angiogenesis. Dr. Berger has authored more than 40 scientific publications and five books.

**********

**WIB, Thursday Evening, April 27, 2017**

Topic: "Hot Trends in Personalized Medicine"
Panel: Moderator, Amy Swanson, Illumina; Jackie Benson, J&J Innovations; Tara Maddala, Grail;Kristin McDonald Gibson, Invitae; Pam Garzone, Pfizer
Date and Time: Thursday, April 27, 2017, 5:30 p.m. – 8:00 p.m. PST
Location: Illumina, 499 Illinois St., San Francisco, CA 94158
Cost: Members - $20 and nonmembers - $50
Details and registration at http://womeninbio.org/eventdetails.aspx?EventId=31271

Event Description
Rapid advances in sequencing and genomics have resulted in greater access to genomic data collection and analysis. With costs decreasing and speed of sequencing increasing, genomic data can be efficiently interpreted and applied to treat and prevent disease in a practical setting. Removing the barriers between benchtop and bedside enables researchers and physicians to capitalize on these technological advances and deliver high quality personalized health care.

Join us for an insightful panel discussion that will touch on several facets of personalized medicine, including targeted therapeutics, immunology, liquid biopsy, and genetic testing. The panel will be moderated by Amy Swanson, Illumina, and feature the following:

Jackie Benson, J&J Innovations
Tara Maddala, Grail
Kristin McDonald Gibson, Invitae
Pam Garzone, Pfizer

Learn more and register for this event.
Registration Deadline
April 26, 2017

Event Sponsor
https://www.illumina.com/
Address:
SanFrancisco@WomenInBio.org
https://www.linkedin.com/groups/Women-In-Bio-San-Francisco-4433988?gid=4433988https://twitter.com/SFWomenInBiohttps://www.facebook.com/WomenInBioSF?ref=br_rs

**Bio2Device Group, Tuesday Morning, May 2, 2017**

Topic: "Current Trends in Animal Models for Preclinical Evaluations"
Speaker: Félix Vega, VMD, Principal Consultant, Preclinical Consultation
Date and Time: Tuesday, May 2, 2017, 8:30 am
Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale
There are no fees nor registration required for morning meetings,

Topic Description
This presentation will provide an overview of the use of animal models in preclinical evaluations, primarily of medical devices. We will briefly discuss the regulatory and ethical requirements of animal use, but concentrate on the utility of animal models in various clinical applications ranging from gastrointestinal through endovascular and cardiac devices. The speaker will present issues raised in recent submissions to the FDA.
Speaker Bio
Félix Vega, VMD, is currently the Principal at Preclinical Consultation. He consults on the full spectrum of preclinical evaluation, with an emphasis on in-vivo studies for medical devices. With his experience in the medical device industry, as well as CRO and university settings, Dr. Vega brings an additional breadth to his training as a veterinarian.
Dr. Vega started in preclinical research at Berkeley Antibody Company, which was at the time the only CRO serving the San Francisco medical device industry. From there he then went on to direct the preclinical program of a start-up device company specializing in collagen-based tissue sealants and adhesives. That company, Fusion Medical Technologies, was acquired by the BioSurgery division of Baxter Healthcare, where he served as the Director of Medical Affairs, BioSurgery-North America. In these capacities as well as in his consultancy practice, Dr. Vega actively participated in the successful submission of multiple successful IND, IDE and 510(k) applications to the FDA, as well as obtaining international regulatory approval and product launches throughout the European and Asian markets as well. These submissions have ranged from delivery devices through hemostatic and sealant biomaterials, as well as device-biologic and device-drug combinations.
Dr. Vega has also played a key role in multiple product launches and the development and implementation of training programs for sales and technical personnel for a variety of medical devices and biomaterials, as well as surgeons and surgical staff throughout Europe, Japan, Canada and Australia.
Dr. Vega completed his undergraduate work at the University of California at Davis and received his doctorate in Veterinary Medicine and Surgery from the University of Pennsylvania. During a decade of private practice, his emphasis was in the medicine and surgery of exotic animals. He is co-inventor on 15 patents and has authored numerous scientific publications and presentations. He serves as an Industry Advisor to the Biomedical Engineering Program at San José State University, where he is a guest lecturer.

**WIB-San Francisco Bay Area, Tuesday, May 2, 2017**

Topic: "Breakthrough Discoveries in Aging Research"
Panelists:

- Rochelle (Shelley) Buffenstein (Staff Scientist, Calico)
- Dena Dubal (Assistant Professor, UCSF)
- Rachel Brem (Associate Professor, Buck Institute)
- Danica Chen (Associate Professor, UC Berkeley)

Date and Time: Tuesday, May 2, 2017,5:00 p.m. – 8:30 p.m. PST
Program
5:00 p.m. – 5:30 p.m. Check-in

5:30 p.m. – 6:00 p.m. Networking and Refreshments
6:00 p.m. – 7:30 p.m. Panel Discussion and Q&A
7:30 p.m. – 8:30 p.m. Networking

Location: Calico, 1170 Veterans Blvd. South San Francisco, CA, 94080
Pricing Information

- Members: $35
- Non-Members: $65
- First 10 Students to register: $25; email SanFrancisco@womeninbio.org to obtain a discount code
- Special pricing available for Calico employees

Details and registration at http://womeninbio.org/eventdetails.aspx?EventId=31327

Topic Description
Can scientists slow down aging? Come learn about the latest discoveries and research in aging from expert academia and industry scientists. The panelists will discuss cutting edge research being conducted in the field of aging, identify important research trends and technologies used in this rapidly growing field, and speak to current as well as future intervention and therapeutic strategies for age-related disorders.

## Registration Deadline

April 25, 2017
**********
**JLABS Bay Area, Tuesday Mid Day, May 2, 2017**

Topic: "Money Matters - Insider Tips on Raising Money"
Speaker: Julie Papanek, Partner, Canaan Partners
Date and Time: Tuesday, May 2, 2017, 10:30 am – 1:00 pm
Agenda:
10:30 AM | Registration and Networking
11:00 AM | Presentation
11:30 AM | Q&A
12:00 PM | Food and Networking
1:00 PM | Program Close
Fees:
$25 | General Public
$15 | Student
$45 | At the door
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor,South San Francisco, California
Order at https://www.eventbrite.com/e/money-matters-insider-tips-on-raising-money-tickets-32167293240?aff=weekly

Speakers Bio
Julie Papanek is a Partner at Canaan Partners where she concentrates on biopharmaceutical, digital health and consumer medical device investments. Julie currently sits on the board of Protagonist Therapeutics (PTGX) and has also worked closely with and observed on the boards of CytomX, Labrys Biologics, Dermira, ALDEA Pharmaceuticals, Chrono Therapeutics, and Glooko. Prior to Canaan, Julie

worked at Genentech in a variety of positions spanning marketing, development, and business development.

Julie earned her MBA from Stanford¹s Graduate School of Business, MPhil from Cambridge in BioScience Enterprise and B.S. from Yale in Molecular Biophysics and Biochemistry.

**Bio2Device Group, Tuesday Evening, May 9, 2017**

Topic: "Liquid Biopsies: A Fundamental Advance in Cancer Care"
Mark Jacobstein, Chief User Engagement Officer, Guardant Health
Date and Time: Tuesday, May 9, 2017
Location: Wilson Sonsini Goodrich & Rosati - 650 Page Mill Road, Palo Alto
Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Register at www.bio2DeviceGroup.org

Topic Description
Liquid Biopsies use circulating biomarker signals (e.g. circulating tumor DNA) found in blood to characterize, and potentially even detect, cancer tumors. Their growth in clinical use for advanced cancer therapy selection is just the start; potential uses include residual disease and early disease detection, and their insights into tumor-genesis and tumor-evolution may be a key for cancer research. Mark Jacobstein, the Chief User Engagement Officer at Guardant Health, the world's leaders in liquid biopsies, will give an overview of this new technology and its current and potential future utility.

Speaker Bio
Mark is the Chief User Engagement Officer for Guardant Health, the world's leaders in liquid biopsies. Mark was the CEO of iSkoot before selling the company to Qualcomm, where he led Qualcomm iSkoot Technologies. Prior Mark was an EVP at loopt, and the founding President of Digital Chocolate. Mark was the CEO and founder of Small World Sports, the world's first online fantasy sports business, which he sold to Paul Allen's The Sporting News. In 1994 Mark co-founded Small World Software, an Internet technology consultancy, which he sold to iXL in 1998
**********

**QB3, Late Thursday Afternoon, May 11, 2017**

Topic: "Leadership in Biopharma: a Conversation with John Milligan, CEO of Gilead Sciences"
Speakers: John Milligan, CEO, Gilead Sciences; Harold E. "Barry" Selick, Ph.D. CEO, Threshold; Brook Byers, Founding Partner of Kleiner Perkins Caufield & Byers
Date and Time: Thursday Afternoon, May 11, 2017, 4:00 – 6:30 pm
Agenda
4:00 pm Introduction: Brook Byers, Partner, Kleiner Perkins Caufield & Byers
4:00-5:00 pm Remarks from John Milligan, Gilead Sciences, followed by audience Q&A and a conversation moderated by Barry Selick, Threshold Pharmaceuticals
5:00-6:30 pm Reception

Location: Byers Auditorium, Genentech Hall, Byers Auditorium, Genentech Hall, UCSF Mission Bay, 600 16th Street. San Francisco, CA 94158
4:00 to 5:00 pm, Thursday, May 11. Reception to follow
Registration is free. Register at https://www.eventbrite.com/e/leadership-in-biopharma-a-conversation-with-john-milligan-ceo-gilead-sciences-tickets-32902967662?mc_eid=cb4c38a44a&mc_cid=c37eecb250#tickets

Background
Gilead Sciences is a Bay Area titan, a life science leader known for its pipeline of antivirals and Hepatitis C therapeutics. Its CEO is John F. Milligan, PhD, a former UCSF postdoc, who joined the company in 1990 as its 32nd employee. Join us on May 11 when Barry Selick, CEO of Threshold Pharmaceuticals and himself a former UCSF postdoc, will engage Milligan in a conversation touching on topics such as Milligan's career path from postdoc to CEO of a major biotech, his experience leading it, and how Gilead feeds its pipeline of innovation and develops new products.
Brook Byers, a Founding Partner of Kleiner Perkins Caufield & Byers and a member of the UCSF Board of Overseers, will provide introductory remarks.

Speaker Bio
Dr. John F. Milligan joined Gilead Sciences in 1990 and was appointed Chief Executive Officer in March 2016. He began his career at Gilead as a research scientist, and subsequently held leadership positions in project management and corporate development before being named Chief Financial Officer in 2002. He was appointed Chief Operating Officer in 2007 and President in 2008.
During his tenure at Gilead, Dr. Milligan has led teams that have developed, manufactured and commercialized more than 20 new therapies for significant unmet needs. He has managed multiple transformative acquisitions, licensing agreements and financings, helping the company grow into a worldwide organization reaching more than 10 million patients. He is a member of the board of Pacific Biosciences of California, Inc. and a Trustee of Ohio Wesleyan University.

Harold E. "Barry" Selick, Ph.D. joined Threshold as Chief Executive Officer in June 2002. Between June 2002 and July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company that was acquired by ArQule. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Brook Byers is a Founding Partner of Kleiner Perkins Caufield & Byers. A venture capital investor since 1972, Brook has been closely involved with more than 60 new technology-based ventures, many of which have become public companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare and biotechnology sectors. KPCB has invested in and helped build more than 170 life

sciences companies that have developed hundreds of products to treat underserved medical needs for many millions of patients. Brook was the founding president and then chairman of four biotechnology companies that were incubated in KPCB's offices and went on to become public companies with an aggregate market value of more than US$8 billion. He serves on the board of directors of Cell Design Labs, Enjoy, Newsela and Zephyr Health. Brook is also a Lifetime Director on the UCSF Board of Overseers.

**Bio2Device Group, Tuesday Morning, May 16, 2017**

Topic: "Why Can't We Just Produce New Brain Neurons and Reverse Neurodegenerative Disease?"
Speaker: Judith Kelleher-Andersson, Founder, President and CEO, Neuronascent, Inc.
Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale
There is no registration or fees for morning meetings.
Topic Description
There is only marginal, symptomatic relief for the approximately 5.3 million Americans thought to already suffer from Alzheimer's disease (AD). With a decade of failures for neuroprotective agents alone, Neuronascent discovered and developed a therapy that would not just stop further neuron loss and dysfunction, but that would promote new neurons that survive to maturation, replacing those lost. This first-in-class, neuron regenerative agent should then halt or even reverse the memory impairment in Alzheimer's patients. The unique mechanism of action was only determined after the identification of a lead candidate through a phenotypic screening platform and optimization program. Neuronascent aims to submit an IND to the FDA for NNI-362 for Alzheimer's disease in 2017. The NIA supported a pre-IND meeting with the FDA and supported all of the FDA-required GLP safety studies showing the agent to be safe. On obtaining FDA approval to initiate the first-in-human testing of NNI-362 for Alzheimer's disease, Neuronascent aims to determine the safety, tolerability and PK in a healthy volunteers aged 50-72. Male and female volunteers will be administered a single dose of NNI-362 orally at one of three ascending doses (SAD) , with and without food. This will be followed by a 14-day daily ascending dose (MAD) test. Plasma levels of NNI-362 will be assessed to determine pharmacokinetics and whether a pharmacodynamic dose has potentially been reached. If NNI-362 is deemed safe and well-tolerated, the agent could then be tested for ability to promote new neurons and halt or reverse cognitive deficits and reverse impaired function in Alzheimer's patients in POC trials.

Speaker Bio
Dr. Kelleher-Andersson has over twenty years of experience discovering and developing small molecule, central nervous system therapeutics in the biotechnology industry. She has raised equity of over 2 million and obtained a number of state and federal grants related to novel therapeutic development. After founding Neuronascent, Kelleher-Andersson discovered and developed a number of technologies. One lead therapeutic is a first-in-class neuron regenerative agent, that is patented and has competed all GLP safety testing, GMP manufacturing and brings the lead to point of IND application to begin first-in-human testing in healthy aged population.
Prior to founding Neuronascent, Inc, she directed drug development research at Neuralstem, Inc., at Centaur Pharmaceuticals and at Cortex Pharmaceuticals, Inc. She strategically directed research/development and personnel toward finding innovative therapies for neurological indications with large unmet need. She headed the Alzheimer's disease program in collaboration with Astra-Zeneca while at Centaur, and successfully brought a small molecule therapeutic to pre-nomination status (primary inventor). She is primary inventor on a neurogenic depression therapeutic, while at Neuralstem, that is presently in Phase 2b clinical testing. Dr. Kelleher-Andersson has over 70 US, European and

World patents. She received her Ph.D. in biochemistry from the University of Missouri-Columbia and completed post-graduate work at University of California, Los Angeles and at University of California, San Francisco.

**********

**BioPharma PM Conference, Monday-Wednesday, May 22-24, 2017**

Event: Stepping Up and Stepping Out
Dates: Monday, Tuesday and Wednesday, May 22-24, 2017
Program:
May 22
5:00-7:00PM: Registration and Opening Networking Reception
May 23
7:30-9:00AM: Registration and Breakfast Networking
9:00AM-5:00PM: Conference Presentations, Panels, Workshops
5:00-7:00PM: Evening Networking Reception
May 24
7:30-9:00AM: Breakfast Networking
9:00AM-2:30PM: Conference Presentation, Panels, Workshops
2:30PM: Conference Conclusion
Location: San Mateo Marriott San Francisco Airport, 1770 South Amphlett Boulevard, San Mateo, CA 94402
Registration: Early Bird Registration (through March 31): $695 (plus payment processing fees); Regular Conference Registration (after March 17): $895 (plus payment processing fees); All registrants will receive a complimentary one-year BioPharmaPM Network membership (a $50 value).
Register at https://www.eventbrite.com/e/2017-biopharmapm-conference-tickets-31937261208

Event Description
Please join us for the 2017 BioPharmaPM Network Conference! We are planning an exciting program for you. Below are a few of our featured speakers, panelists, and trainers who will speak on diverse topics such as managing your career in alignment with your values, leadership development in project management, and how you can solve problems inhibiting project success easily and effectively.

Speakers: William Schiemann, Founder and CEO of Metrus Group and Author; Jean Lee, Ph.D., Vice President, Portfolio and Project Management at Pfizer Global Product Development; Michael Young, Chief Learning Officer and SVP of Education at the The Medicines Company;Mark Velligan, Senior Director of Portfolio Management and Operations at Genentech;Trevi Wormley, Managing Director and Chief Solution Engineer at TJ Strategy Group, LLC

We hope you will join us at the San Mateo Marriot in San Francisco May 22-24 and be a part of the only non-profit organization solely committed to project management best practices, development, and networking for biopharma project and program managers.

FAQs
How can I contact the organizer with any questions?
For questions, please contact Kelly Magnuson at kmagnuson@biopharmapm.org

How do I make room reservations?
We are holding a few rooms at a discounted rate with the San Mateo Marriott. If you require a room, please email Kelly Magnuson at kmagnuson@biopharmapm.org for details.

**Bio2Device Group, Tuesday Morning, May 25, 2017**

Topic: "A Clinical Trial Roadmap: Who, What, When, and How – Practices, Perspectives and Personal Insights"
Speaker: David Larwod, CEO, Valley Fever Solutions
Date and Time: Tuesday, April 25, 8:30 am
Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale

Topic Details
While many of us conceptually understand the clinical trial process, a deeper dive will provide essential information regarding the parties involved, the risks, structuring and optimizing clinical archicture, design, efficiency, visibility, and more. What are the recommended practices? What is Just-inTime Monitoring? How should you manage your supply chain? How do you select the best CRO? The key is to understand the elements and thus ensure smooth navigation throughout the complex clinical trial landscape and journey. There are a myriad of drugs in clinical trials, each with a story to tell.
Valley Fever Solutions' (VFS) first-in-class compound, Nikkomycin Z (NikZ) is being developed as a dramatically superior potential cure for Valley Fever (VF), a painful and debilitating orphan disease. Collectively, the market for anitfungals across a spectrum of similar disease organisms approaches $1B. Broadly and worldwide, the market reaches $6B. With Orphan Product designation, NikZ's Phase I trial results have been very promising, and VFS has a "fast track" plan to proof of concept in 10 months.They anticipate showing human efficacty working with an existing trial at the NIH. VFS expects to be a good candidate for an additional $1.5M FDA orphan drug product trial grant in 2017. Join us and learn from a true expert's professional and personal journey.

Speaker Bio
David Larwood has been a chemist for decades, most recently leading Valley Fever Solutions since 2007 as its CEO. His PhD research at UC San Francisco included the world's first PEGylated liposomes, later leading to Doxil. He was the first to make suitable PEGylated lipids. Earlier, at UC San Diego, he was the first ever to make Iotrolan, a contrast agent still in commercial use 37 years later.
Valley Fever Solutions is a small startup working first on a new and improved treatment for Valley Fever (coccidioidomycosis). Since securing grant support to continue with Phase II trials, Mr. Larwood has been leading improving the API manufacturing process, working on drug product, planning for clinical trials, and organizing the trials.
Mr. Larwood moved away from being a bench scientist when he took a law degree. He advised well known companies on patent matters until he moved to a position at Apple Computer for four years. He took an executive role at a startup, again in an IP role. He then moved to another startup taking Verisity Design public as General Counsel, continuing in that role through a successful acquisition in 2005. David also received an MBA in entrepreneurship from UC Berkeley and Columbia University.
Mr. Larwood is the third of his family to be involved in Valley Fever. His father is a clinician who developed an interest in the disease decades ago when the family moved to Bakersfield, California, a hot spot for Valley Fever. His mother started a foundation in about 1998 and raised some $20M for research into vaccines for Valley Fever. Her chief scientist was the program manager at Shaman running the Nikkomycin Z drug development project.

Timing was perfect for Mr. Larwood to join Valley Fever Solutions in 2007 to drive that project forward.

**********

**JLABS, Tuesday Morning, May 23, 2017**

Topic: "Rough seas or smooth sailing? Navigating Collaboration Agreements"
Speakers:
Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP
Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation
William J. Newell | CEO, Sutro Biopharma
Moderator: Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Date and Time: Tuesday, May 23, 2017 from 9:00 AM to 11:30 AM (PDT)

Agenda:
9:00 AM | Registration, Breakfast, and Networking
9:30 AM | Components of a collaboration agreement
10:00 AM | Panel Discussion: Implications of Components
11:00 AM | Q&A
11:30 AM | Program Close
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
Fees:
$25 | General Public
$15 | Student
Order at https://www.eventbrite.com/e/rough-seas-or-smooth-sailing-navigating-collaboration-agreements-tickets-32071988180?aff=weekly

Event Details
How do you develop a smart collaboration agreement? An effectively written collaboration agreement builds and strengthens a productive scientific relationship by allowing parties to enter into a mutually beneficial relationship.

How do you make sure the agreement will fit your company objectives? An effective agreement should be clear, to both the research workers and managers of both parties, laying the groundwork for moving the results of research toward commercialization. It addresses the nature of the collaboration, the responsibilities and obligations of each party, the desired outcomes and next steps beyond the currently contemplated research.

At this event, we will walk through building components of a collaboration agreement, point out and discuss key terms and provisions that help make a quality agreement. The talk with provide real world examples and focus on the following topics:
Intro to Collaboration Agreements / General provisions
Statement of objectives/work
Budget
IP
Restrictions and opportunities created by agreements
Real world examples from panel members

The panel members will share real life experiences through the R&D collaboration process and beyond. The workshop will examine key types of provisions and their effects on future development and funding opportunities. This "how to" workshop is geared towards life sciences startup
Guests will be provided supporting materials including:
Key provisions guide
Sample Collaboration agreements
This event is being hosted in conjunction with Deloitte. Deloitte is deeply committed to the life sciences industry. As an advisor to many leading health care and life sciences organizations, Deloitte has been instrumental in developing and implementing many strategies that helped shape the evolution and long-term success of this industry. At Deloitte, we serve from early-stage companies to the world's largest players. We know where you go and we can help you to realize your dreams. As with all our events, the "How to…Workshop" is informal and interactive so bring your questions with you!

Speakers' Biographies:

Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP
Angela has 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, offerings in leveraged buyouts, and several secondary shares offerings. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.

Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation
Yelda is the Senior Director of Transactions in Johnson & Johnson Innovation Center, California.
Leveraging a diverse career practicing emergency medicine, corporate law and business development, Yelda brings extensive experience to transactions delivering a unique breadth of deals across sectors with an established track record of successfully leading, structuring, negotiating and executing complex deals over the last 10 years.
Yelda joined the Johnson & Johnson family from GSK's worldwide business development group. She holds a MBBS, LLB and MBA from the University of Melbourne.

William J. Newell | CEO, Sutro Biopharma
Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio. Mr. Newell is also a Board member on BIO's Emerging Companies Section and a member of the Board and of the Executive Committee of the California Life Sciences Association.

Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Dr. Stolz has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. After two years negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center, Lesley joined the JLABS team as Head of JLABS, CA, to participate in the mission of helping to catalyze new companies in the healthcare ecosystem. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. During her career she has work on over 45 collaboration agreements helping shape effective opportunities for early stage companies. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.
**********

**PBSS Minisymposium, Friday, June 2, 2017**

Event: Drug-Induced Liver injury (DILI): risk assessment in drug discovery and clinical development
Speakers: William Treem (J&J), Michael Rothenberg (Genentech), Weida Tong (NCTR/FDA), Yazen Alnouti (UNMC), Donna Dambach (Genentech), Cyrus Khojasteh (Genentech), Kenneth Brouwer (Qualyst), Gary Peltz (Stanford Medical)
Date and Time: Friday, June 2, 2017, 9:00 -16:00
Location: Crowne Plaza, Foster City, CA
Registration fee (USD): Regular: $195; Academic: $125; Students & Unemployed: $35;
Registration: http://www.PBSS.org
Further Information:
Registration deadline: 5/31/2017 (it will close sooner if the seating cap is reached)

Topic Description
Drug-induced liver injury (DILI) continues to be a leading cause of attrition during small molecule drug development, withdrawal post-marketing, and cautionary / restrictive labeling. Hepatotoxicity risk is difficult to predict based on the various etiologies that encompass DILI, with unknown factors driving patient susceptibility towards hepatic stress and injury, coupled with the poor concordance of preclinical species to identify human hepatotoxicants in vivo. However, retrospective analysis over the past 50 years has identified several factors associated with DILI that include but are not limited to physicochemical properties of the drug, dose, metabolism and disposition, and signals in a battery of in vitro assays. As such, the pharmaceutical industry and regulatory agencies alike are focused on more comprehensive risk assessment to reduce and/or mitigate DILI risk in drug discovery and early development. This full-day mini-symposium is centered on contemporary perspectives on DILI from an academic, industry, and regulatory perspective, with focused talks addressing mechanisms of DILI, clinical presentation and management, hepatotoxicity risk assessment in drug discovery, and novel tools (including biomarkers) emerging in the field.

Minisymposium topics and speakers:
TBD - William Treem, MD, J&J

The challenges of potential DILI in early clinical development - Michael Rothenberg, MD, PhD, Genentech
Liver Toxicity Knowledge Base – A knowledge base approach for drug-induced liver injury - Weida Tong, PhD, NCTR/FDA
The role of bile acids in DILI and liver diseases - Yazen Alnouti, PhD, University of Nebraska Medical Center (UNMC)
Multi-parametric assessment of hepatotoxicity risk in drug discovery - Donna Dambach, VMD, PhD, Genentech
Reactive metabolites: from assessment to removal in drug discovery - Cyrus Khojasteh, PhD, Genentech
Risk Assessment for Cholestatic Hepatotoxicity: Integrating Transporter Inhibition and FXR Mediated Regulation into a Predictive In Vitro Assay - Kenneth R. Brouwer, PhD, RPh, Qualyst Transporter Solutions
Human Liver Engineering: From Safer Drugs to Liver Regeneration - Gary Peltz, MD, PhD, Stanford University Medical School

**WIB Plenary Session, Monday Late Afternoon, June 19, 2017**
Event: Plenary Event at BIO Convention: "Pitch Perfect Challenge"
Date and Time: Monday, June 19, 2017, 4:30 p.m. – 7:30 p.m. PST
Location: Manchester Grand Hyatt, 1 Market Place,San Diego, CA 92101
Fees: Member - $60 and Non Member - $90
Details and registration at http://womeninbio.org/eventdetails.aspx?EventId=31272
On-Line Registration Deadline

Event Description
Inviting. Supporting. Succeeding.

Adjacent the Biotechnology Innovation Organization (BIO) International Convention, please join us for our signature annual WIB Plenary Event on Monday, June 19, 2017, at the beautiful Manchester Grand Hyatt from 4:30 p.m. - 7:30 p.m.
The evening will open with keynote speaker Carol Gallagher, Pharm.D, Partner of New Enterprise Associates, with a presentation discussing the investment landscape and an overview of fund-raising challenges and trends.
We then move into our Pitch Challenge where women leaders in the life sciences will deliver pitches and receive valuable feedback from top female investors on presentation and delivery. If you're up for the Challenge, please apply here by Friday, April 28, 2017. Please complete the application and attach your slide deck in an email to Pitch@womeninbio.org. Participation Eligibility Criteria and Official Rules are listed in the application. Please note that we only review non-confidential materials.
The Pitch Challenge will be moderated by Simone Fishburn, BioCentury Innovations, and our prestigious panel of judges include:

- Nina Kjellson, Caanan Ventures
- Margarita Chavez, AbbVie Ventures
- Kristina Burow, ARCH Partners
- Heather Behanna, Sofinnova
- Marianne De Backer, Johnson & Johnson
- Carol Gallagher, NEA

As with all Women In Bio events, our Plenary Event encompasses an inviting and fun environment for networking as it brings together people from all corners of the life sciences industry, and spawns new career and business opportunities.
This event is not to be missed so register today!

**********

**JLABS, Tuesday Morning, June 20, 2017**

Event: "Meet with… Novartis Venture Fund"
Date and Time: Tuesday, June 20, 2017 from 10:30 AM to 1:00 PM (PDT)
Agenda:
9:00 AM | Registration, Breakfast, and Networking
9:30 AM | Components of a collaboration agreement
10:00 AM | Panel Discussion: Implications of Components
11:00 AM | Q&A
11:30 AM | Program Close

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due May 19, 2017. Apply Here.
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
Ticket Information
Fees:
Presentation
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on June 20 (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Apply to meet one-on-one with representatives from Novartis Venture Fund. Your application will be reviewed and you will be notified of acceptance on Monday June 6, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Event Details
Let's get more solutions to patients. The Johnson & Johnson Innovation, JLABS (JLABS) Meet with… Series helps life sciences entrepreneurs, as well as the academic community, connect with potential partners including corporate venture, VC's, Angels and other investment entities.

On June 20th Principal Christine Brennan and Life Sciences Investment and Operations Professional Giovanni Ferrara of the Novartis Venture Fund (NVF)team will be in attendance to give an overview presentation about the fund's key areas of interest and to meet 1-on-1 with companies that have been accepted after applying online.

Program Overview:
The Novartis Venture Fund founded in 1996, currently manages over $750 Million in committed capital, and has investments in ~40 portfolio companies globallyb>. NVF's strategy is to build a diverse portfolio of life science companies, across:
Biotechnology/biopharma
Medical device/diagnostics

Digital/eHealth
NVF is stage agnostic and engages in seed investments as well as later-stage investments, typically investing up to $15 - $20 million over the life of the company. In investing, NVF looks for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency.

Following the presentation, don't miss this opportunity to introduce yourself to the team during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Novartis Venture Fund will provide an intimate forum to discuss your company

Speaker Bios:
Christine Brennan | Principal, Novartis Venture Fund
Dr. Brennan joined the Novartis Venture Fund in November 2013. Prior to joining Novartis Venture Fund, Dr. Brennan spent 3 years at Vitae Pharmaceuticals as Chief Business Officer responsible for strategy & business development. Prior to Vitae, she spent 5 years at Novartis Institutes for BioMedical Research in Strategic Alliances, most recently as Executive Director and Head of Strategy & Operations. Prior to Novartis, she held positions in business development and marketing at the biopharmaceutical companies, EnVivo Pharmaceuticals (now FORUM Pharmaceuticals), Biovail (now Valeant Pharmaceuticals) and Cogent Neuroscience. In addition, she was Director atFidelity Biosciences Group (now F-Prime Capital Partners), a venture capital company. She received her Ph.D. in neuroscience from Dartmouth Medical School in 1995 and completed a postdoctoral fellowship at the National Institutes of Health in 1999.

Giovanni Ferrara | Life Sciences Investment and Operations Professional, Novartis Venture Fund

**BIO Talent Connect, 6.22.2017**
BIO Talent Connect presented by BioSpace
San Diego Convention Center
Ballroom 20AB
Register at
http://www.biospace.com/jobs/seekersignin.aspx/?ReferPage=/jobs/careerfairregister.aspx?careerfairid=293
Thursday, June 22, 2017
2:00pm to 6:30pm
Register Now

**About BIO Talent Connect**

BIO Talent Connect is not another career fair. It's a unique opportunity to network with peers, industry leaders and hiring managers at the hottest biopharma companies in an open, inviting and efficient format.

BIO International Convention is the largest global gathering of life sciences innovators and the optimal place to bring leading employers together with talented professionals.

**Who should attend?**

All Life Sciences professionals are invited to attend, including PhD and Postdoc candidates as well as professionals with Life Sciences experience in any discipline. Your resume is required to register.

**What companies will be there?**

Company leaders, scientists and hiring managers are looking forward to meeting you at BIO Talent Connect to discuss a wide variety of global career opportunities. A full list of companies will be posted to this page prior to the event.

**Should I still register if I can't attend?**

Yes! If you are unable to attend the event, but interested in life science career opportunities, you should still register as soon as possible. Employers will be able to view your resume and contact you.

**********